Germany imported 50,539 kg of medical cannabis flower in Q1 2026, and Canadian producers supplied 26,753 kg of it, or 53%, according to BfArM figures reported by StratCann. A lot of that flower never carries the grower's name. It reaches German pharmacies under an importer's product name, packed and released inside the EU.
Private-label cannabis supply is an arrangement in which a Canadian Licensed Producer grows, dries and tests bulk flower. An EU importer then packages, releases and sells it under its own product name. The grower owns the cultivation record. The importer owns the brand, the pack and the legal responsibility for placing the product on the market.
On paper, the model is simple. The friction sits in cultivar naming, retest results and irradiation status. A 2025 dispute in Germany showed how quickly a naming shortcut can cost an importer its pharmacy distribution.
How private-label cannabis supply works
A private-label programme runs on one chain of custody with two sets of regulators. Each link has an owner, and each owner produces documents the next link depends on.
- The Licensed Producer cultivates under a Health Canada licence issued under the Cannabis Act, following GACP practices for the starting material.
- The producer harvests, dries, cures and trims each lot, then tests it at a laboratory accredited to ISO/IEC 17025.
- Health Canada issues an export permit for the shipment, matched to the importer's BfArM import permit.
- An EU-GMP certified site in the EU handles any further processing, packaging and quality control testing.
- A Qualified Person certifies the batch, and the importer places it on the German market under its product name.
Why Canadian branding rules don't travel with bulk flower
Canada's plain-packaging rules, including the health warning and standardized cannabis symbol, apply to cannabis products packaged for retail sale. Bulk flower exported for packaging at the destination is not a cannabis product under the Cannabis Regulations. Section 138 only requires its container to show the exporting licence holder's name, telephone number and email address, plus the lot number and packaging date.
That rule is what makes private label structurally possible from Canada. The producer ships a labelled lot, and the importer builds the brand in the EU.
Why the importer's name is on the pack
Under section 9 of the German Medicines Act (AMG), every medicinal product sold in Germany must carry the name and address of the pharmaceutical entrepreneur responsible for it. In a private-label deal, that party is the importer. What matters in a private-label deal is whose documentation stands behind each named product, and that answer should be written into the contract.
Who owns what in a private-label cannabis agreement
Most disputes in private-label supply come from a responsibility nobody wrote down. The split below reflects how the chain is built under Canadian and German rules. Your quality agreement should state each line explicitly.
| Responsibility | Canadian LP | EU importer |
|---|---|---|
| Cultivation and GACP records | Owns and maintains | Audits before first order |
| Pre-export COA | Issues per lot | Checks against agreed specification |
| Canadian export permit | Applies per shipment | Supplies import permit copy |
| BfArM import permit | Not applicable | Applies per shipment |
| EU-GMP processing and packing | Supplies batch documentation | Owns or contracts the site |
| QP batch certification | Supplies batch record | Its QP certifies release |
| Product name and label | No brand on bulk containers | Owns under AMG section 9 |
| Cultivar identity per product | Guarantees the named cultivar | Keeps one cultivar per product |
The 2025 naming dispute that made this concrete
On August 26, 2025, counsel for a German cannabis company sent a legal warning to a competing importer. The letter alleged that the importer sold several cultivars under a single drug name and approval number, contrary to the AMG. According to StratCann, it pointed to BfArM expectations that each medicinal product, including each distinct cultivar, carries its own application and entry number.
Within a week, one of Germany's central pharmacy distribution platforms told the pharmacies it serves that it would stop carrying that importer's products. The importer rejected the allegations and called the matter one of administrative interpretation. The commercial damage landed anyway, before any regulator had commented publicly.
For importers, the lesson is structural. A private-label product name is one cultivar, lot after lot. If your supplier can't guarantee that in writing, treat the programme as spot buying and price the risk accordingly.
The 5-term private-label supply checklist
These five terms decide whether a private-label programme survives its first year. We call it the 5-Term Private-Label Checklist, and every term belongs in the signed supply agreement or quality agreement.
1. Cultivar lock and substitution rules
Name the cultivar, its genetic source and the product name it supplies. Then state what happens when a crop fails: the shipment is delayed, or a different cultivar ships under a separate product name. Buyers who want a deeper test of this should read our guide to cannabis cultivar consistency.
2. Specification and COA acceptance
Set the THC and CBD ranges, contaminant limits and moisture criteria the lot must meet. Agree which laboratory result governs if numbers differ, because EU release testing rarely matches the Canadian COA to the decimal. Our breakdown of why EU retest results differ from the COA covers the usual causes.
3. Irradiation status
Declare in writing whether each lot was treated with ionising radiation. Germany restricts irradiated medicinal products under section 7 of the AMG, and a separate authorisation applies before they can be marketed. Our cannabis irradiation guide for export markets explains what each market expects.
4. Forecast and permit timing
Both permits are issued per shipment and tied to a stated quantity. A rolling forecast lets the producer reserve lots and lets the importer file its BfArM application before the flower is ready, not after.
5. Change control and the quality agreement
Any change to the growing room, drying process, packaging material or testing lab should trigger written notice before the next shipment. The cannabis quality agreement between a Canadian LP and an EU importer is where this obligation lives.
Our view is plain: an importer that signs a private-label agreement without a written no-substitution clause is taking on regulatory risk it can't price.
Where private-label cannabis deals break down
The failure points are rarely exotic. They show up in the same three places, usually within the first few shipments.
Potency drift against the label
The German pack declares THC and CBD content, and the figure the importer can print depends on EU release testing. When a lot tests below the agreed range after arrival, the importer has to relabel, reposition or reject it. Each option costs weeks, and the producer usually learns about it last.
Exclusivity by market
A producer selling the same cultivar to two German importers under two product names creates a price fight on the same pharmacy shelf. Settle exclusivity by cultivar and by market before the first purchase order. Renegotiating it after launch is far harder.
Documentation that arrives after the flower
A lot can sit in a bonded warehouse because a GACP record, a COA revision or a permit copy is missing. The cheapest fix is a document checklist attached to every purchase order, signed off before the shipment leaves Canada.
AlphaLeaf is a Health Canada Licensed Producer in Montreal growing premium indoor, hand-trimmed flower from refined genetics. We export under Cannabis Act authorisation, test every batch at ISO/IEC 17025 accredited laboratories and keep full lot traceability. That lets EU importers building their own product lines hold each product name to a single cultivar.
If you're planning a private-label line for the German medical channel, talk to our export team about cultivar availability and documentation. Start with the cultivar. The brand can wait.
Frequently Asked Questions
What is private-label cannabis supply?
Private-label cannabis supply is an arrangement where a Licensed Producer grows, dries and tests bulk flower, and an importer packages and sells it under its own product name. The producer keeps the cultivation and testing records. The importer carries legal responsibility for the product in its market.
Can a Canadian LP export bulk cannabis without Canadian branding?
Yes. Bulk flower exported for packaging at the destination is not a cannabis product under the Cannabis Regulations. Section 138 only requires the container label to show the exporting licence holder's name, telephone number, email address, lot number and packaging date.
Whose name appears on a private-label cannabis product in Germany?
The importer's. Section 9 of the German Medicines Act requires every medicinal product sold in Germany to carry the name and address of the responsible pharmaceutical entrepreneur. In a private-label deal, that is the importer, not the Canadian grower.
Can one product name cover several cannabis cultivars in Germany?
It shouldn't. A 2025 legal warning to a German importer alleged that selling several cultivars under one drug name breached the German Medicines Act. A major distribution platform dropped the products within a week. Treat each cultivar as its own product.
Who performs the QP release for private-label flower sold in the EU?
A Qualified Person working for the importer or its contracted EU-GMP site certifies each batch before release. The Canadian producer supplies the batch record, COA and cultivation documentation that the QP reviews.
Does private-label supply work for Australia?
It can. In Australia, the local sponsor holds regulatory responsibility for supplying the product, and each batch must meet the TGO 93 quality standard set by the TGA. The producer's role is to supply compliant flower and the documentation the sponsor needs.
